GLP1 News Hour: Access, Policy, Gray Market Risks, and Emerging Research Amanda Bonello and Kristi Turner kick off the first live GLP1 News Hour, introducing the show and laying out what it covers: GLP1 news, policy, FDA decisions, lawsuits, access issues, and the real-world impact of all of it. The episode is equal parts news roundup and candid conversation, with both hosts bringing their own GLP1 journeys and professional backgrounds into the mix.They cover a wide range of developments affecting patients, from employer coverage losses and Medicaid rules to TikTok gray-market scams, pediatric GLP1 research, and new lawsuits. The throughline is access: who gets treatment, who loses it, and what it means when cost, policy, and misinformation collide. Key topics In this episode, Amanda Bonello introduces herself as founder of the GLP1 Studio, founder of the GLP1 Collective, co-founder of Cozy Butter, and cohost of GLP1 News Hour. Kristi Turner shares that she is a licensed mental health counselor, private practice owner, mother of two adult sons, and someone who began her GLP1 journey in May 2024, losing a little over 200 pounds so far. The hosts explain that the show is focused on GLP1 news, policy, FDA decisions, lawsuits, and whatever else is shaping the conversation week to week. In today's news, they discuss employer coverage erosion, including a report that one in 10 employers plans to drop obesity-related GLP1 coverage next year. They note that major employers are already dropping coverage and argue that public advocacy has helped push cash-pay prices down, even while insurance access keeps shrinking. Amanda shares that Novo Nordisk has hired Anthropic to help with AI drug discovery, which opens a broader conversation about AI in medical research and drug development. The hosts discuss the scale of GLP1 use, noting that about 40 million Americans are on a GLP1, including people using them for type 2 diabetes. Kristi explains a Kentucky Medicaid-related access issue, where outdated state rules may prevent the state from participating in a federal model that could lower drug costs for some patients. They break down a TikTok gray-market problem, where more than 200 accounts were identified selling fake GLP1 shots and only about a third were removed. The hosts warn that gray-market products can be dangerous, especially when people are driven there by branded medication costs that can exceed $1,200 a month. Kristi covers a Novo study suggesting 40 percent of children ages 6 to 12 were no longer classified as obese after a 68-week semaglutide study, while also noting that approvals for younger children are still unresolved. Amanda and Kristi talk about how pediatric obesity treatment intersects with family support, peer connection, and the emotional impact of community. In culture news, they discuss restaurant portion sizes shrinking as GLP1 use rises, while prices stay the same. They note that 11 percent of American adults now take a GLP1 for weight loss, up from 3 percent in 2024. The hosts react to a conference panel that framed GLP1s in political terms, including claims that they are being used to "genocide fat people," and push back on the idea that obesity treatment is anti-fat or anti-personhood. Amanda and Kristi discuss celebrity body commentary, including public speculation about Selena Gomez and Ariana Grande, and why bodies should not become a public obsession. They cover a hair-loss study that was reported as GLP1-related but did not actually follow people taking the medication, explaining that rapid weight loss and poor nutrition are more likely contributors to shedding. Kristi shares her own experience with hair thinning, trauma bangs, and regrowth, and Amanda adds that some people are using hair treatments successfully while staying on GLP1s. The episode closes with policy updates on 17 GLP1-related lawsuits, a House bill aimed at PBM reform, and an Illinois workers' comp proposal that could affect compounded semaglutide coverage. The conversation ends with both hosts reflecting on the first live run, what worked, what felt clunky, and how they plan to improve the format next time. Timestamps The GLP-1 News Hour: Episode 1 Chapters Welcome 21:08 Welcome to the GLP1 News Hour 22:42 Kristi's background and GLP1 journey 25:44 Amanda's GLP1 origin story and why the show exists The News 27:00 Employer coverage is still dropping 29:56 Novo Nordisk partners with Anthropic on AI drug discovery 31:59 40 million Americans are on a GLP1 34:35 Kentucky Medicaid access blocked by outdated rules 37:05 Medicaid map shows how limited obesity coverage is 39:55 TikTok gray-market GLP1 sellers and fake shots 45:23 Novo study on GLP1s in children ages 6 to 12 51:31 Restaurants shrink portions but not prices 52:59 GLP1 use for weight loss jumps to 11 percent of adults 55:03 Debate over whether GLP1s are being used "fascistically" 1:02:46 Hair-loss claims and what the evidence actually says 1:08:04 Bariatric surgery trends and side effects support 1:09:56 17 GLP1 lawsuits and what is still unknown 1:12:17 PBM reform bill heads to committee 1:14:49 Illinois workers' comp and compounded semaglutide coverage Wrap-up 1:18:50 Wrapping the first live show and lessons learned 1:27:10 Final sign-off and next steps This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit glp1newshour.substack.com
